Ultragenyx Pharmaceutical Inc


Ultragenyx Pharmaceutical Inc (RARE) Tumbles on Ace-ER Failure; Top Analyst Remains Bullish

Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM

Cowen Analyst Reiterates Outperform on Ultragenyx Pharmaceutical Inc (RARE) Following Positive Clinical Update

At the 14th International Symposium on MPS and Related Diseases, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) presented positive pivotal Phase 3 trial of recombinant human …

Canaccord Reiterates Buy on Ultragenyx Pharmaceutical Inc (RARE) Following Positive Phase 3 Trial

In a research report issued Friday, Canaccord analyst Arlinda Lee reiterated a Buy rating on shares of Ultragenyx Pharmaceutical Inc (NASDA:RARE) with a price …

Piper Jaffray Analyst Bullish on Ultragenyx Pharmaceutical Inc (RARE) Due To Promising Pipeline Drugs

Analyst Steven Breazzano initiated an Overweight rating for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) with a price target of $70, marking an increase of 35% from …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts